| Literature DB >> 23855966 |
Anne Nilsson1, Juscelino Tovar2, Maria Johansson2, Karl Radeborg3, Inger Björck4.
Abstract
BACKGROUND: Disorders such as the metabolic syndrome (MetS), impaired glucose tolerance and diabetes, are associated with increased risk of cognitive decline. Also several of the individual key features that define the MetS, e.g. hypertension, impaired glucose regulation, dyslipidemia, obesity, and inflammation, are related to an increased risk of cognitive decline. Consequently, a diet that prevents metabolic disorders might be expected to prevent cognitive decline. The purpose of the present study was to, in overweight but otherwise healthy subjects, investigate effects on cognitive functions of a dietary regime combining multiple functional concepts potentially beneficial to risk markers associated with MetS. The purpose was in addition to evaluate cognitive performance in relation to results on cardiometabolic risk variables (BMI, blood pressure, glucose, insulin, cholesterol, triglycerides, free fatty acids, lipoprotein A-1 and B, hs-CRP, HbA1c, interleukin-6, TNF-α, and PAI-1).Entities:
Keywords: Ageing; Cognitive decline; Cognitive performance; Crossover design; Diet and cognitive functions; Dietary prevention; Metabolic disease; Metabolic disorders; Metabolic syndrome; Randomized controlled trial
Year: 2013 PMID: 23855966 PMCID: PMC3720285 DOI: 10.1186/1743-7075-10-49
Source DB: PubMed Journal: Nutr Metab (Lond) ISSN: 1743-7075 Impact factor: 4.169
Time schedule for execution of cognitive tests
| Fasting (0 min)1 | X | |
| 30 min | | |
| 45 min | X | |
| 60 min | | X |
| 90 min | | |
| 120 min | X |
1The first SA-test was performed at fasting, directly prior to a standardised breakfast. 2The RAVLT took approximately 60 min to perform. SA selective attention, RAVLT Rey Auditory Verbal Learning Test.
Nutritional profiles of the control and active diet
| | ||||
|---|---|---|---|---|
| Energy (kcal/day)* | 2045 | 2570 | 2100 | 2615 |
| Protein (E%) | 15 | 14 | 19 | 18 |
| Carbohydrate (E%) | 56 | 55 | 51 | 50 |
| Fat (E%) | 29 | 30 | 31 | 31 |
| Saturated fat (E%) | 12.8 | 13.2 | 5.9 | 5.9 |
| Monounsaturated fat (E%) | 10.5 | 11.1 | 13.0 | 13.6 |
| Polyunsaturated fat (E%) | 3.6 | 3.7 | 8.2 | 8.4 |
| ω-6 fatty acids (E%) | 2.9 | 3.1 | 4.2 | 4.3 |
| ω-3 fatty acids (E%) | 0.8 | 0.8 | 2.2 | 2.3 |
| ω-6/w-3 ratio | 3.8 | 3.8 | 1.9 | 1.9 |
| Dietary fiber (g/day) | 22 | 26 | 49 | 61 |
| Cholesterol (mg/day) | 200 | 240 | 140 | 160 |
* Increased energy intake was prescribed for subjects that experienced weight loss during the initial weeks (Table 2 taken from Tovar et. al.[29]).
Proposed functional action and average content of active components in the active diet
| Soybean/soy protein | Cholesterol-lowering, anti-inflammatory [ | 21 | 25 |
| VISCOUS FIBERS | | | |
| b-glucans | Cholesterol- lowering, prebiotic, GI-reducing [ | 5.8 | 6.2 |
| Guar gum | 5.6 | 6.7 | |
| Total | 11.4 | 12.9 | |
| n-3 PUFA (20:5 + 22:6) | Triglyceride-lowering, anti-inflammatory [ | 2.4 | 3.0 |
| Almonds | Cholesterol-lowering [ | 28 | 28 |
| Plant stanols | Cholesterol-lowering [ | 2.0 | 2.7 |
| Cinnamon | Antioxidant [ | 3.0 | 3.0 |
| Blueberries | Antioxidant, prebiotic [ | 74.5 | 94.5 |
| Vinegar | GI –reducing [ | 22.5 | 22.5 |
| Probiotic | Anti-inflammatory [ | 0.1 (1010 CFU) | 0.1 (1010 CFU) |
| Whey protein* | GI-reducing [ | 4.3 | 4.3 |
*Whey protein (10 g) was only consumed simultaneously with high GI meals (potatoes, parsnip), 3 times per week.
Correct responses in the SA-test after 4 weeks consumption of the active- versus the control diet
| | ||
|---|---|---|
| time 0 | 67.3 ± 2.5 | 65.6 ± 2.5 |
| 45 min | 73.4 ± 2.4 | 74.0 ± 2.1 |
| 120 min | 76.5 ± 2.4 | 73.1 ± 2.5* |
1 SA-test: selective attention test, max 95 credits.
*: p < 0.05 for the differences in performance after the active diet in comparison to after the control diet at 120 min. Data are given as means per treatment ± SEM, time = 0: n = 40, time = 45: n = 42, time = 120: n = 40.
Reaction times in the SA-test after 4 weeks consumption of the active- versus the control diet
| time 0 | 1320 ± 20 | 1320 ± 21 |
| 45 min | 1219 ± 19 | 1230 ± 21 |
| 120 min | 1182 ± 21 | 1202 ± 23 |
1 SA-test: selective attention test.
Data are given as means per treatment ± SEM, time = 0: n = 40, time = 45: n = 42, time = 120: n = 40.
Performance in the RAVLT after 4 weeks consumption of the active- versus the control diet
| 1: List 1 | 12.0 ± 0.73 | 11.3 ± 0.64 |
| 2: List 1 | 16.8 ± 0.73 | 15.9 ± 0.80 |
| 3: List 1 | 20.1 ± 0.72 | 20.0 ± 0.75 |
| 4: List 1 | 21.8 ± 0.71 | 21.8 ± 0.77 |
| 5: List 1 (best learning) | 22.7 ± 0.68 | 22.9 ± 0.74 |
| 1-5: List 1 (mean learning 1–5) | 18.6 ± 0.65 | 18.4 ± 0.69 |
| 6: List 2 (PI) | 9.3 ± 0.62 | 9.6 ± 0.70 |
| 7: List 1 (RI) | 21.0 ± 0.80 | 20.7 ± 0.86 |
| 8: 20 min pause. List 1 | 21.7 ± 0.80 | 21.7 ± 0.95 |
| 9: List 3 (Recognition) | 28.0 ± 0.51 | 27.2 ± 0.69* |
| 10: List 1 (Order of listed nouns) | 17.1 ± 0.64 | 16.0 ± 0.59 |
1 RAVLT: The Rey Auditory-Verbal Learning test.
*: p < 0.05 for the differences in performance in RAVLT no. 9 after the active diet in comparison to after the control diet. Data are given as means per treatment ± SEM, n = 42. PI proactive interference, RI retroactive interference.
Associations between performance in the SA-test(CR and RT)and cardio-metabolic risk markers after the active- and the control diet, respectively, obtained with regression analyses (model 1 and model 2)
| | CR | RT | CR | RT | ||||||||
| MODEL 1: | R2: 0.28 | R2: 0.35 | R2: 0.21 | R2: 0.29 | ||||||||
| Adj- R2: 0.17 | Adj- R2: 0.26 | Adj- R2: 0.11 | Adj- R2: 0.19 | |||||||||
| P < 0.05 | P < 0.01 | P = 0.1 | P < 0.05 | |||||||||
| MODEL 2: | coef | (std Err) | beta | coef | (std Err) | beta | coef | (std Err) | beta | coef | (std Err) | beta |
| Total- cholesterol | (416) | −0.37 | (22) | 0.32 | (244) | −0.33 | - | | | |||
| ApoA1 | - | | | - | | | - | | | - | | |
| Systolic BP | - | | | (0.97) | 0.40 | - | | | (1.1) | 0.36 | ||
| Glucose | - | | | - | | | - | | | - | | |
| Const. | (1812) | (153) | (1453) | (144) | ||||||||
1SA selective attention. 2CR correct responses, RT reaction time.
3Cardio-metabolic risk markers included in model 1 are: systolic blood pressure, fasting concentrations of total cholesterol, Apo A-1, insulin, and glucose. Model 2 includes test variables revealing significant associations with cognitive performance after step-wise, one-by-one elimination of non-significant test markers in model 1.
*: p < 0.05, **: p < 0.01. n = 42.
Associations between performance in the RAVL (trials no. 1–10) and cardio-metabolic risk markers after the active diet, obtained with regression analyses (model 1 and model 2)
| MODEL 1. | R2: 0.32 | R2: 0.31 | R2: 0.30 | R2: 0.30 | R2: 0.24 | R2: 0.17 | ||||||||||||
| Adj- R2: 0.22 | Adj- R2: 0.21 | Adj- R2: 0.21 | Adj- R2: 0.20 | Adj- R2: 0.14 | Adj- R2: 0.04 | |||||||||||||
| P < 0.05 | P < 0.05 | P < 0.05 | P < 0.05 | P = 0.07 | P = 0.29 | |||||||||||||
| MODEL 2. | coef | (std Err) | beta | coef | (std Err) | beta | coef | (std Err) | beta | coef | (std Err) | beta | coef | (std Err) | beta | coef | (std Err) | beta |
| Total- cholesterol | - | | | - | | | - | | | - | | | - | | | - | | |
| ApoA1 | (3.1) | 0.32 | - | | | (3.8) | 0.34 | (157) | 0.30 | - | | | (3.3) | 0.36 | ||||
| Systolic BP2 | (0.04) | −0.40 | - | | | (0.04) | −0.37 | (1.7) | −0.31 | - | | | - | | | |||
| Glucose | - | | | (0.28) | −0.37 | - | | | - | | | (1449) | −0.36 | - | | | ||
| Const. | 21.6 | (6.6) | 5.4 | (0.98) | 22.5 | (8.0) | 382 | (327) | 42288 | (7930) | 6.0 | (4.7) | ||||||
*: p < 0.05, **: p < 0.01. n = 43.
1 Cardio-metabolic risk markers included in model 1 are: systolic blood pressure, fasting concentrations of total cholesterol, Apo A-1, insulin, and glucose. Model 2 includes test variables revealing significant effects on cognitive performance after step-wise, one-by-one elimination of non-significant test markers in model 1. 2BP blood pressure.
Associations between performance in the RAVL (trials no. 1–8)and cardio-metabolic risk markers after the control diet, obtained with regression analyses (model 1 and model 2)
| MODEL 1. | R2: 0.18 | R2: 0.19 | R2: 0.30 | R2: 0.35 | ||||||||
| Adj- R2: 0.16 | Adj- R2: 0.06 | Adj- R2: 0.21 | Adj- R2: 0.25 | |||||||||
| P < 0.01 | P = 0.21 | P < 0.05 | P < 0.01 | |||||||||
| MODEL 2. | coef | (std Err) | beta | coef | (std Err) | beta | coef | (std Err) | beta | coef | (std Err) | beta |
| Total cholesterol | - | - | | - | | | - | | | - | | |
| ApoA1 | (109) | 0.43 | (0.51) | 0.37 | (142) | 0.48 | (141) | 0.54 | ||||
| Systolic BP3 | - | - | | - | | | - | | | - | | |
| Glucose | - | - | | - | | | - | | | - | | |
| Const. | −143 | (169) | 1.0 | (0.80) | −282 | (220) | −363 | (217) | ||||
1 Performance in trial no 9–10 did not reveal significant effects of metabolic risk markers, and the results are therefore not shown in the table.
2 Cardio-metabolic risk markers included in model 1 are systolic blood pressure, fasting concentrations of total cholesterol, Apo A-1, insulin and glucose. Model 2 includes test variables revealing significant effects on cognitive performance after step-wise, one-by-one elimination of non-significant test markers in model 1. 3BP blood pressure.
*: p < 0.05, **: p < 0.01, ***: p < 0.0001.
Pearson correlations between Reynold- and Framingham risk scores and performance in the SA-test (mean of tests no. 1–3)
| | ||||
|---|---|---|---|---|
| Reynold 10 years risk | −0.19 | −0.18 | 0.32* | 0.46** |
| Framingham 10 years risk | −0.03 | 0.07 | 0.16 | 0.33* |
1SA-test selective attention test.
*: p < 0.05, **: p < 0.01.
Pearson correlations between Reynold- and Framingham risk scores and performance in the RAVLT no. 1–9)
| Cardiovascular risk score | Active diet | Control diet | Active diet | Control diet | Active diet | Control diet | Active diet | Active diet | Active diet | Control diet |
| Framingham risk score | −0.43** | −0.46** | −0.29§ | −0.38* | −0.42** | −0.37* | −0.41** | −0.41** | −0.40** | −0.42** |
| Reynold risk score | −0.55*** | −0.55*** | −0.33* | −0.37* | −0.48** | −0.48** | −0.52*** | −0.52*** | −0.43** | −0.46** |
1 RAVLT: The Rey Auditory-Verbal Learning test 1–9, no significant effects were detected in trial no. 10.
*: p < 0.05, **: p < 0.01, ***: p < 0.0001, §: p < 0.1.